{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-24-000197","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.807278+00:00","generated_at":"2026-05-30T02:55:59.194702+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Humacyte Q3 net loss $39.2M; ATEV BLA review ongoing with no new timeline","bullets":["Net loss $39.2M (Q3 2024) vs $26.0M (Q3 2023) driven by non-cash contingent earnout remeasurement.","Cash $71M at Sep 30; received $29.6M net from Oct registered direct offering.","FDA BLA for ATEV in vascular trauma still under review; no new PDUFA date provided.","V007 Phase 3 AV access data presented at ASN Kidney Week: ATEV superior patency vs fistula in key subgroups.","Submitted NTAP reimbursement application to CMS for FY2026 cycle (Oct 2025 effective date if approved)."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-24-000197","json":"https://secwatch.observer/filing/0001818382-24-000197.json","markdown":"https://secwatch.observer/filing/0001818382-24-000197.md","text":"https://secwatch.observer/filing/0001818382-24-000197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000197/0001818382-24-000197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000197/huma-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:55:59.194702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}